Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. - Wikidata - awgldk - TriplyDB

Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.

Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.

http://www.wikidata.org/entity/Q34994511

about

Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination Immunity to Pathogens Taught by Specialized Human Dendritic Cell Subsets Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond Vaccines for the 21st century Immunotherapy in gastric cancer Intradermal electroporation of naked replicon RNA elicits strong immune responses Whole blood cells loaded with messenger RNA as an anti-tumor vaccine.Generation of more effective cancer vaccines Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one.Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin.Nonviral delivery of self-amplifying RNA vaccines.Biomaterials for mRNA delivery.Developing mRNA-vaccine technologies.Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals.Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy.Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals Induction of Protective Immunity against Toxoplasma gondii in Mice by Nucleoside Triphosphate Hydrolase-II (NTPase-II) Self-amplifying RNA Vaccine Encapsulated in Lipid Nanoparticle (LNP).mRNA vaccination as a safe approach for specific protection from type I allergy.MUC1 immunotherapy is here to stay.mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge.Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise.Cancer vaccination by electro-gene-transfer.HLA ligandome tumor antigen discovery for personalized vaccine approach.Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy.The ReNAissanCe of mRNA-based cancer therapy.mRNA transcript therapy.Antigen-specific vaccines for cancer treatment.Electroporation-enhanced delivery of nucleic acid vaccines.Lipid-based mRNA vaccine delivery systems.Update on Mucin-1 immunotherapy in cancer: a clinical perspective.New challenges in therapeutic vaccines against HIV infection.Vectors and strategies for nonviral cancer gene therapy.

P2860

Q26769044-9F5248C9-6192-4BCF-97E9-C522BC798B1D Q26777195-DEF33FDD-8669-4843-ABED-0DFE935D13F8 Q26861563-9B4DD259-48E7-4FA9-B9AB-6C029C14FBA9 Q27007529-B6B9B13E-FB0F-4BDA-90F3-63D672314F44 Q27010472-8B8DF941-7629-44A2-B433-E3A04382147B Q27310340-31AF6F01-044D-44A7-8A48-A0BAAECFADCD Q33740816-850A7C48-898F-432C-87EE-59A85AA8C886 Q34169981-8C0112A8-E9FE-4830-AF6D-B0D4A98615C9 Q34494018-26B96130-0064-4F77-A95A-92C0463BF511 Q34870799-6EB635A0-0EB8-4CF0-BFC1-583C450F64E6 Q35652459-7E4CC02D-6199-4F63-992F-DE7F5619299E Q35746834-64688ACE-5F58-4106-B103-82132504E068 Q35886889-75BC9365-164F-49D9-848A-7291AF566235 Q35939486-5D64417A-F6B3-4083-8754-9AF004C39821 Q36221799-DD4E54CA-9CDD-4FAD-9F8D-1FCC7398173D Q36271488-BCD59F16-82BD-47D0-BC73-A6A6070C036A Q36684597-ED9E9E5A-457B-4470-BEC0-71FC16062421 Q36757051-05A82F54-BA7C-4C36-B253-4D6DF450BC88 Q37012691-067757EB-1624-474C-9492-1677D5AAE824 Q37126611-4DD8A769-FAF9-4E26-8163-3C594BDBF2A5 Q37612455-258B19AA-BEF4-4C1A-A1DF-C09887282BD1 Q37737615-1B613C66-1145-46C3-8FBA-725052FDE5F7 Q37965722-6F9CC8B2-B01A-4C97-B45A-8BD41DD9BAFF Q38045428-24EBFF95-CBB6-48E0-8EBF-81FFE04E3E08 Q38071900-C49EEC29-36A9-4B93-8416-94AC3988B113 Q38091088-1DCBC587-2402-4EC7-94E7-F4C12717AF93 Q38113267-588B449F-DC14-477A-A58E-C3B9BD77E352 Q38143182-2120C2DA-B8F5-4863-96D4-3A332B4333D6 Q38148779-3C0495A4-C5E2-4FAF-B954-A51974AA12C6 Q38199151-D5C0429A-C368-43F8-9FB9-BB4B3B67565D Q38206520-D3C29AD9-BEC9-4634-AF3A-F3F825DC302F Q38217593-36B36512-AD70-4795-89D6-DD69EC48A3A7 Q38255012-21C88AAD-812F-4E7F-BCBA-4FC719AEA99E Q38264088-90398360-D8D4-4B03-A410-F4B818F7CD04 Q38284692-FE7F7393-09ED-4F0A-8F8F-496E2D4A7999 Q38285418-7BB69D09-EFC6-4872-AE4E-048EFDFF768C Q38300777-8B0FBF88-D137-4DBD-8C50-E12D9D63A32C Q38603410-69487384-F863-41FE-A82A-40A7510C1C1F Q38692205-BA56E01A-7CD6-4A54-9FA7-85DE09BE0C56 Q38694798-4F1448A9-2F55-4F7D-AC38-0D5735D525F6

P2860

Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.

http://www.wikidata.org/entity/Q34994511

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Intradermal vaccinations with ...... enefit in vaccinated patients.

@ast

Intradermal vaccinations with ...... enefit in vaccinated patients.

@en

Intradermal vaccinations with ...... enefit in vaccinated patients.

@nl

type

label

Intradermal vaccinations with ...... enefit in vaccinated patients.

@ast

Intradermal vaccinations with ...... enefit in vaccinated patients.

@en

Intradermal vaccinations with ...... enefit in vaccinated patients.

@nl

prefLabel

Intradermal vaccinations with ...... enefit in vaccinated patients.

@ast

Intradermal vaccinations with ...... enefit in vaccinated patients.

@en

Intradermal vaccinations with ...... enefit in vaccinated patients.

@nl

P1433

Q34994511-52184DE9-91DF-4FCA-A565-AB2D8EF1C42A

P1476

Q34994511-1784336B-9CC9-484B-9F7B-4B77D426DAA4

P2093

Q34994511-13698DDE-4DF4-45D2-9875-4E61E9D82203

Q34994511-176AE950-CB83-4123-8D3B-155A116BE340

Q34994511-3645EEB0-DD3B-4300-870E-387B2331B5B9

Q34994511-449F7CAF-4E6D-4D79-960F-BA49D2C936C1

Q34994511-4DF6BF6E-5663-4BAB-AA70-32C2DA956995

Q34994511-685CC5C4-A287-433F-9A5C-5DEC15E50E83

Q34994511-762E8588-F04A-44E6-A7F8-AA400715C70E

Q34994511-7DC40B04-0ED4-4921-9AC0-A4E1B5722831

Q34994511-9E950333-43E7-47DE-90A0-FD796F9C5C6A

Q34994511-9F7C2F77-6714-4F94-B7CC-D165F76EA74F

P2860

Q34994511-1504FF73-D381-42A0-AF4F-8B766D789594

Q34994511-1856BFBD-A5E7-473B-805F-5794898A1ACA

Q34994511-18BFC0AB-6300-4612-B63F-B5CC38445B56

Q34994511-232E52A4-5030-4806-AFA4-5B56CF65CC6E

Q34994511-2B59EA8C-D688-431F-8AD5-1AF543A65501

Q34994511-321527BD-A309-4C5C-B709-DFCE44F38C0D

Q34994511-39F1C7B5-091C-40A8-A561-78CED61A2BBC

Q34994511-3A769B06-365F-4FBE-B34E-D3E5D212DEB8

Q34994511-4D428011-80B8-4461-A612-8DD4623C3DCD

Q34994511-4EC35932-6458-4A6E-8F2F-61551EB6DB16

P304

Q34994511-2AC20B98-F65C-4BAE-9E4C-33D92EC950B5

P31

Q34994511-843BD807-806A-46CA-A41B-2BC75B6139CF

P356

Q34994511-EC4451AD-38F3-4BAE-9C12-C924340F604E

P433

Q34994511-EE67E9E1-9B3B-43D1-B44C-C0CCC3FB4D61

P478

Q34994511-47046D7B-1F48-4156-A96F-16FFF6BB7C5E

P50

Q34994511-48E53472-E42D-4975-8B78-6DB0D923565E

P577

Q34994511-FF4A7475-2225-42AA-BBA8-A239FFB3E48C

P5875

Q34994511-42A651A5-249F-40BC-B5E3-1A8095F1F896

P698

Q34994511-151C2A0A-6218-40ED-A2F2-5D7AD880D391

P921

Q34994511-F92F4AD3-F80B-42D1-8071-C486408561C0

P932

Q34994511-455F8076-39D7-4492-80F4-47DC11A08C26

P356

P1433

Molecular Therapy

P1476

Intradermal vaccinations with ...... enefit in vaccinated patients.

@en

P2093

Annkristin Heine

http://www.w3.org/2001/XMLSchema#string

Arnulf Stenzl

http://www.w3.org/2001/XMLSchema#string

Ingmar Hoerr

http://www.w3.org/2001/XMLSchema#string

Katrin J Weimer

http://www.w3.org/2001/XMLSchema#string

Lothar Kanz

http://www.w3.org/2001/XMLSchema#string

Maik Haentschel

http://www.w3.org/2001/XMLSchema#string

Marius S Horger

http://www.w3.org/2001/XMLSchema#string

Martin R Muller

http://www.w3.org/2001/XMLSchema#string

Olga Maksimovic

http://www.w3.org/2001/XMLSchema#string

Peter Brossart

http://www.w3.org/2001/XMLSchema#string

P2860

Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas.

In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies.

Results of the first phase I/II clinical vaccination trial with direct injection of mRNA.

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

A listing of human tumor antigens recognized by T cells.

Renal-cell carcinoma.

Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies.

Messenger RNA-based vaccines.

Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARgamma ligand troglitazone.

BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.

P304

990-999

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2010.289

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Georg Rammensee

P577

2010-12-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49712856

http://www.w3.org/2001/XMLSchema#string

P698

21189474

http://www.w3.org/2001/XMLSchema#string

P921

P932

3098631

http://www.w3.org/2001/XMLSchema#string